Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
antimalarial |
| gptkbp:approvalYear |
2018
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
P01BA15
|
| gptkbp:brand |
Arakoda
Krintafel |
| gptkbp:CASNumber |
106635-80-7
|
| gptkbp:chemicalFormula |
C24H28F3N3O3
|
| gptkbp:contraindication |
gptkb:G6PD_deficiency
|
| gptkbp:developedBy |
GlaxoSmithKline
|
| gptkbp:drugClass |
antiprotozoal
|
| gptkbp:eliminationHalfLife |
~15 days
|
| https://www.w3.org/2000/01/rdf-schema#label |
tafenoquine
|
| gptkbp:indication |
malaria prophylaxis
radical cure of P. vivax malaria |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
8-aminoquinoline antimalarial
|
| gptkbp:pregnancyCategory |
Not recommended
|
| gptkbp:PubChem_CID |
132029
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
hemolytic anemia in G6PD-deficient patients
|
| gptkbp:synonym |
WR 238605
|
| gptkbp:UNII |
6J0A5V5877
|
| gptkbp:usedFor |
prevention of malaria
treatment of Plasmodium vivax malaria |
| gptkbp:bfsParent |
gptkb:Plasmodium_vivax
|
| gptkbp:bfsLayer |
5
|